Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

NCT07641023 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Advanced/Metastatic

Interventions

BIOLOGICAL: Dual-target CAR-NK cells
DRUG: Lymphodepleting chemotherapy
OTHER: Supportive care

Sponsor

Beijing Biotech